First filing for Chugai's ALK contender alectinib, in Japan
This article was originally published in Scrip
Roche's Japanese subsidiary Chugai has submitted the first approval application globally for alectinib (AF802/RG7853), seeking approval of the second-generation oral anaplastic lymphoma kinase (ALK) inhibitor in Japan for the treatment of non-small cell lung cancer (NSCLC).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.